ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) has commenced the multiple ascending dose (MAD) study testing the first-in-class therapeutic antibody ASLAN004 in moderate to severe atopic dermatitis (AD) patients. The company has also opened clinical sites in the US and Australia and also starting enrolling patients. The patients will now enroll from 3 sites in the US, 4 sites in Australia, and 2 existing sites in Singapore.
ASLAN004 is a first-in-class monoclonal antibody that combines with the IL-13 receptor α1 subunit (IL-13Rα1). It also blocked the signaling of two pro-inflammatory cytokines, IL-4 and IL-13. These cytokines are central to activate symptoms of AD, such as redness and itching of the skin.
ASLAN Pharmaceuticals has recently started the enrollment in the second cohort of double-blind, placebo-controlled studies in Singapore after the government has lifted the coronavirus restrictions. All 8 patients have been enrolled in the cohort and the company is planning to start enrollment into the third cohort after approval by the Data Monitoring Committee.
Furthermore, 8 patients will be enrolled in Singapore, the US, and Australia. ASLAN expects to report interim, unblinded data from all 3 dose cohorts in 4Q 2020.
ASLAN Pharmaceuticals, Inc. (NASDAQ: ASLN) shares were trading up 15.71% at $1.92 at the time of writing on Wednesday.
ASLAN Pharmaceuticals, Inc. share price went from a low point around $0.35 to briefly over $8.18 in the past 52 weeks, though shares have since pulled back to $1.92. ASLAN market cap has remained high, hitting 72.40 Million at the time of writing.
The company has earlier participated in H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020.